Menarini builds new facilities to support MEN1309 program

Italian drugmaker Menarini has expanded its manufacturing capabilities for oncological drugs, with new, dedicated facilities in Pisa, Italy, and Berlin, Germany.

In Pisa, a new site for the production of clinical batches of antitumoral compounds will manufacture both small molecules and biological macromolecules such as antibody-drug conjugates (ADCs).

The new facilities will initially be used to manufacture clinical batches of MEN1309, a candidate under co-development with Oxford BioTherapeutics, for the treatment of solid and hematological tumors.